Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04747977 · ClinicalTrials.gov registry record · Phase 2

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

A Phase 2 study, sponsored by Ocular Therapeutix.

Completed
Registry status
Phase 2
Development phase
172
Enrollment target

NCT04747977: Completed Phase 2 study, sponsored by Ocular Therapeutix.

NCT04747977 is a Phase 2 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 172 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04747977, a Phase 2 study, has completed, sponsored by Ocular Therapeutix.

COMPLETED
Registry status
Phase 2
Development phase
172 participants
Enrollment target

Study Summary

To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.

Primary Outcome

The primary efficacy endpoint is photographic assessment of bulbar conjunctival hyperemia \[evaluated by the central reading center (CRC)\] in the study eye, change in score from baseline (CFB) at Visit 4 (Day 15). Scoring is from 0 (None) to 4 (Severe) on the CCLRU Grading Scale for Bulbar Conjunctival Hyperemia.

Interventions

  • DRUG OTX-DED

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2021-02-12
Est. Completion 2021-09-22
Phase Phase 2
Ocular Therapeutix

20 total trials

What the finished NCT04747977 record still lists

NCT04747977 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher).

The record links to 0 conditions, and to 1 intervention - of which OTX-DED is the first listed.

NCT04747977 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04747977 about?

NCT04747977 is a clinical study titled "To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease". To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.

What is the current status of trial NCT04747977?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2021-02-12. Estimated completion is 2021-09-22.

What interventions are being tested in trial NCT04747977?

The interventions under investigation include: OTX-DED (DRUG).

Who is sponsoring clinical trial NCT04747977?

This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04747977's enrollment target sits among peer trials

172 397th of 2000 higher than 1,603 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04801797 · 172 participants · Phase 2

    Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

  • NCT04867317 · 172 participants · Phase 3

    Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

  • NCT05357040 · 172 participants · Phase 2

    Antidepressant Effects of Nitrous Oxide

  • NCT05587517 · 172 participants · Phase 2

    A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04747977, the US trial registry maintained by the National Library of Medicine. NCT04747977 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.